Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
Zymeworks Inc.
organization4 mentionslast seen Oct 23, 2026
Biotechnology company that completed acquisition of Theravance Biopharma.
Relationships 9
- Zymeworks Inc.acquiresTheravance Biopharma, Inc.99% confidence2 sources
- Zymeworks Inc.developsZiihera99% confidence2 sources
- Zymeworks Inc.employsKenneth Galbraith99% confidence2 sources
- Zymeworks Inc.ownsTheravance Biopharma, Inc.99% confidence1 source
- Zymeworks Inc.employsAdam Schayowitz96% confidence1 source
- F. Hoffmann-La Roche Ltdpartners withZymeworks Inc.95% confidence1 source
- Zymeworks Inc.funded byTheravance Biopharma acquisition financing95% confidence1 source
- Zymeworks Inc.developsZW20990% confidence1 source
- Zymeworks Inc.commercializesYUPELRI90% confidence1 source
Relationship
Zymeworks Inc.developsZiihera
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 23, 2026Zymeworks Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks
- filingSEC EDGARSep 23, 2026Zymeworks Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 2.01: Completion of Acquisition or Disposition of Assets; Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
Ziihera ® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks